Related Experiment Video
Updated: Aug 8, 2026
13:21
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline
1Menzies Research Institute, University of Tasmania, Hobart 7000, Tasmania, Australia. changhai.ding@utas.edu.au
Current Opinion in Investigational Drugs (London, England : 2000)
|May 30, 2006
Summary
Belimumab is a novel antibody therapy targeting B-lymphocyte stimulator (BLyS) for autoimmune diseases. Phase II trials for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complete, with Phase III SLE trials commencing soon.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Autoimmune diseases like SLE and RA involve immune system dysregulation.
- B-lymphocyte stimulator (BLyS) plays a key role in the survival and function of B cells, which are implicated in autoimmunity.
Purpose of the Study:
- To evaluate the efficacy and safety of belimumab, a human monoclonal antibody targeting BLyS, for treating autoimmune conditions.
- To advance belimumab through clinical development for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Main Methods:
- Belimumab is a therapeutic antibody designed to inhibit the activity of BLyS.
- Clinical trials, including Phase II studies in SLE and RA patients, were conducted.
- A Phase III clinical trial for SLE is planned.
Main Results:
- Belimumab has successfully completed Phase II clinical trials for both SLE and RA as of January 2006.
- The drug is progressing towards later-stage clinical evaluation.
Conclusions:
- Belimumab represents a promising targeted therapy for autoimmune diseases.
- Further clinical trials, including Phase III for SLE, are warranted to confirm its therapeutic potential.
